Lundbeck Showcases Long-Term Effectiveness of Eptinezumab in Chronic Migraine
Lundbeck has presented compelling new clinical data on its migraine therapy eptinezumab at the 2025 International Headache Congress (IHC) in São Paulo, underlining the treatment’s durable preventive benefits for patients severely affected by chronic migraine.
The company delivered six presentations in total, including three oral sessions highlighting advances in both eptinezumab and its investigational therapy Lu AG09222.
Central to the new data were findings from the open-label extensions of the RESOLUTION and SUNSET clinical trials, which further strengthen the case for eptinezumab as a long-term treatment option.
RESOLUTION Trial: Sustained Relief in Patients with Medication Overuse Headache
The phase 4 RESOLUTION trial focused on patients living with chronic migraine complicated by medication overuse headache. Results demonstrated sustained reductions in monthly migraine days (MMDs), with around 50% of patients achieving at least a 50% reduction from baseline.
On average, participants experienced a decrease of nine MMDs over 12 weeks, showing that eptinezumab can deliver meaningful, lasting relief even for those with more complex migraine profiles.
SUNSET Trial: Long-Term Efficacy in Japanese Patients
The SUNSET trial, a 60-week extension of the earlier SUNRISE study in Japanese patients, provided further confirmation of eptinezumab’s long-term impact. By weeks 49–60, 35.7% of participants achieved a 50% reduction in MMDs, with a growing proportion showing ≥75% response rates over time.
These results underscore eptinezumab’s ability not only to provide early benefit but also to sustain and even deepen treatment responses over extended periods.
Safety Profile Remains Consistent
Across both trials, eptinezumab was well tolerated, with a safety profile in line with previous clinical studies and existing prescribing information in the United States and EU.
No new safety signals were identified, offering reassurance for physicians and patients alike regarding the treatment’s long-term use.
A Commitment to Chronic Migraine Patients
Commenting on the findings, Lundbeck’s Executive Vice President and Head of Research & Development emphasised that patients deserve preventive migraine treatments that provide both early relief and enduring effectiveness.
They also noted that the RESOLUTION and SUNSET trials demonstrate how patients who respond early to eptinezumab tend to maintain those responses over time.
Conclusion
The latest data presented at IHC 2025 strengthen the evidence base for eptinezumab as a durable and effective preventive option for chronic migraine sufferers worldwide.
By confirming both sustained efficacy and consistent safety across diverse patient populations, Lundbeck has reinforced its commitment to improving outcomes for those living with the burden of migraine.
For patients and clinicians seeking reliable, long-term solutions, eptinezumab continues to stand out as a therapy capable of delivering lasting impact.
News Credits: Lundbeck unveils migraine data for eptinezumab at international congress
Things you may also like: